FDA — authorised 19 December 2019
- Application: NDA212895
- Marketing authorisation holder: CSPC OUYI
- Local brand name: CONJUPRI
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 LEVAMLODIPINE MALEATE in United States
FDA authorised LEVAMLODIPINE MALEATE on 19 December 2019
Marketing authorisations
FDA
- Status: approved
LEVAMLODIPINE MALEATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is LEVAMLODIPINE MALEATE approved in United States?
Yes. FDA authorised it on 19 December 2019; FDA has authorised it.
Who is the marketing authorisation holder for LEVAMLODIPINE MALEATE in United States?
CSPC OUYI holds the US marketing authorisation.